Ann Gils - Concepedia

Author

Ann Gils

Also Known As

A Gils, A. GILS, A. Gils, A. L. T. van Overbeek – van Gils, A.L.T. van Overbeek- van Gils, Ann Gils, Chris Neeleman, GILS A, GILS A, Paul J. Declerck

331

Publications

11.3K

Citations

H-Index

147

Concepts

All Affiliations

KU Leuven Universitair Ziekenhuis Leuven University of Liège AZ Delta Research & Diagnostic Antibodies (United States)

About

Ann Gils is an author at KU Leuven specializing in medicine, pharmacology, and inflammation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	65	4.6K
2	Natural Sciences	15	17	698
3	Engineering	9	9	205
4	Health Sciences	3	3	73
5	Public Health	2	2	83

Ann Gils

157

Publications

9.7K

Citations

H-Index

Page 1

	Year	Citations
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease Niels Vande Casteele, Marc Ferrante, Gert Van Assche, Gastroenterology Trough ConcentrationsInflammationAnti-inflammatoryGastroenterologyPharmacotherapy	2015	859
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient Niels Vande Casteele, Ann Gils, Sharat Singh, The American Journal of Gastroenterology	2013	342
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease Geert D’Haens, Séverine Vermeire, Guy Lambrecht, Gastroenterology InflammationChronic Inflammatory DiseasesInfliximab DoseImmunologyGastroenterology	2018	295
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease Niels Vande Casteele, Reena Khanna, Barrett G. Levesque, Gut	2014	283
The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent Laetitia Devy, Silvia Blacher, Christine Grignet‐Debrus, The FASEB Journal PharmacotherapyCellular PhysiologyTumor BiologyMolecular PharmacologyAngiogenesis	2002	281
Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD Konstantinos Papamichael, Ann Gils, Paul Rutgeerts, Inflammatory Bowel Diseases ImmunologyGastroenterologyPathologyTnf AntagonistsPharmacotherapy	2014	237
Immunogenicity of biologics in inflammatory bowel disease Séverine Vermeire, Ann Gils, Paola Accossato, Therapeutic Advances in Gastroenterology	2018	224
Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays Niels Vande Casteele, D. J. Buurman, Marieke G. G. Sturkenboom, Alimentary Pharmacology & Therapeutics	2012	207
Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications Maarten Bloemen, Ward Brullot, Tai Thien Luong, Journal of Nanoparticle Research	2012	200
A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis Maria Theresa Arias, Niels Vande Casteele, Séverine Vermeire, Clinical Gastroenterology and Hepatology InflammationAnti-inflammatoryGastroenterologyInfliximab TherapyUlcerative Colitis	2014	184

Page 1